Although there are various treatment options for cancer, this disease still has caused an increasing number of deaths, demanding more efficient, selective and less harmful drugs. Several classes of ruthenium compounds have been investigated as metallodrugs for cancer, mainly after the entry of imidazolH [-RuCl-(DMSO-S)(imidazole)] (NAMI-A) and indazolH [-RuCl-(Indazol)] (KP1019) in clinical trials. In this sense, Ru complexes with general formula [Ru(L1-3)(bipy)]PF (1-3) (L1 = ethyl 3-(6-methyl-2-oxo-2-chromen-3-yl)-3-oxopropanoate, L2 = ethyl 3-(7-(diethylamino)-2-oxo-2-chromen-3-yl)-3-oxopropanoate, L3 = ethyl 3-(8-methoxy-2-oxo-2-chromen-3-yl)-3-oxopropanoate and bipy = bipyridine) have been synthesized.
View Article and Find Full Text PDF